Murphy Nicole, Biogen’s (BIIB) Head of Pharm Ops and Tech, has demonstrated a clear selling bias in her recent trading activity, with $1.44 million in total sales compared to just $585 in purchases across 28 transactions. Her trades are exclusively concentrated in Biogen, with no activity in other companies. The bulk of her sales occurred in February 2026, including three large dispositions on February 6 totaling $671,740 ($283,261, $183,879, and $204,600). Earlier sales in February 2025 and February 2024 followed a similar pattern, with multiple transactions in quick succession, such as $95,502 and $172,871 across two days in February 2025. The only recent buy was a modest $585 acquisition on February 12, 2026, following an award transaction the next day with no reported value. This pattern suggests a consistent disposition of equity, likely tied to vested awards or planned sales, given the recurring February timing across multiple years. The absence of meaningful buying activity reinforces a net reduction in her position, though the transactions appear systematic rather than discretionary, given their regularity and concentration around annual intervals.
AI-assisted summary